57 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
is elected and has been qualified, or until their earlier death, resignation or removal.
In connection with resolutions 1 and 2, we set forth … herself for re-appointment, or until her earlier death, resignation or removal. Dr. Jallal has agreed to serve if re-appointed, and our board
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
includes directors; and
a contract relating to a pension, superannuation or similar scheme or a retirement, death, disability benefits scheme
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
their successor is elected and has been qualified, or until their earlier death, resignation or removal.
In connection with resolutions 1 and 2, we set … by rotation and offer herself for re-appointment, or until her earlier death, resignation or removal. Dr. Jallal has agreed to serve if re-appointed
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
which includes directors; and
a contract relating to a pension, superannuation or similar scheme or a retirement, death, disability benefits scheme
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
the first dose (0.3 mcg). In accordance with our own internal guidelines, we put our clinical trial on hold to investigate this unexplained death … . After autopsy, including expert review, and other investigations, the primary investigator concluded that the cause of death was respiratory failure
10-K
EX-10.12
2wi2tgt25 6v0
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
0h91ii3 1h1p59hwao5k
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
hc8hxbkg2hmo0b2x n2
28 Feb 24
Annual report
7:33am
6-K
EX-99.1
6w1i8g
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
6uj 39w5q1bfw
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.4
n9ftdbjx
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
pksf 5h1icnb7d
30 Sep 22
Prospectus with selling stockholder info
4:15pm
6-K
EX-99.1
32gc6z ihm
9 Sep 22
Cautionary Note Regarding Forward Looking Statements
4:29pm
424B5
dtn5eevhaurzyhsc 7wr
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.2
bofhfgt v1
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.1
ku5xpklh8epw6eryf50
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
yc3rs0qm hft6w2hz
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
424B7
hv7ik il30
5 May 22
Prospectus with selling stockholder info
12:00am
F-3ASR
pyxwm
4 Apr 22
Automatic shelf registration (foreign)
4:08pm